Study Explores Rise in Early-Onset Cancers

(MENAFN) A recent investigation proposes that the growing rates of early-onset cancer among American adults under 50 could primarily stem from improved and more frequent detection, rather than a genuine surge in disease occurrence.

Published on Monday in the journal JAMA Internal Medicine, the study outlines how several cancer types—including those of the thyroid, kidney, small intestine, colorectum, endometrium, pancreas, and myeloma—have seen their rates double since 1992.

However, researchers suggest that this rise may largely be attributed to heightened diagnostic attention and overdiagnosis, rather than a true escalation in cases.

For example, the report notes that overdiagnosis is particularly well established in thyroid and kidney cancers. In other cancer types, earlier recognition through advanced screening methods may be responsible for the uptick in reported cases.

Crucially, the study emphasizes that death rates have not increased in tandem with diagnosis rates, indicating that many of these additional cases might not represent dangerous or life-threatening disease.

“While not among the fastest growing (0.6% per year), breast cancer remains the most common early-onset cancer, and despite rising diagnoses in women younger than 50 years, mortality has decreased by approximately half,” the study said.

The findings lead researchers to conclude that the increase in early-onset cancer rates “does not consistently signal a rise in the occurrence of clinically meaningful cancer.”

In other words, while some of the growth in case numbers may reflect real medical concerns, it seems to be limited to only a few types of cancer and is not widespread across all forms.

Ultimately, the research suggests a nuanced view: although some early-onset cancers are indeed rising for legitimate clinical reasons, much of the observed increase may be due to better awareness, testing, and identification—rather than a true escalation in serious cancer cases.

MENAFN01102025000045017167ID1110134508